Cytek Biosciences, Inc. (CTKB) Misses Q3 EPS by 1c, Beats on Revenue

Cytek Biosciences, Inc. (NASDAQ: CTKB) reported Q3 EPS of ($0.04), $0.01 worse than the analyst estimate of ($0.03). Revenue for the quarter came in at $52.3 million versus the consensus estimate of $51.03 million.

For earnings history and earnings-related data on Cytek Biosciences, Inc. (CTKB) click here.

You May Also Be Interested In

• Corning (GLW) files for up to $2B offering of common shares
• HSBC Downgrades Iflytek Co Ltd (002230:CH) to Hold
• AstraZeneca's camizestrant fails primary endpoint in breast cancer trial